At 18.8% CAGR, the Asia Pacific Whole Slide Imaging Market is projected to be worth US$ 309.94 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the Asia Pacific whole slide imaging market was valued at US$ 110.48 million in 2022 and is expected to reach US$ 309.94 million by 2028, registering an annual growth rate of 18.8% from 2022 to 2028. Raising adoption of digital pathology and upraising developments in telemedicine technologies.                

Increasing emphasis on achieving better diagnostic outcomes is extensively driving the demand for digital pathology. Growing acceptance of digital pathology and whole-slide imaging is universal among academic health centers, pathology departments, and the nation’s largest pathology companies. Many private practice pathology groups in the United States now recognize that digital pathology is the path forward for the entire profession. Most academic pathology departments and large pathology lab companies have integrated digital pathology (DP) and whole-slide imaging (WSI) into many of their lab’s daily activities. This growing demand for digital pathology solutions is expected to increase the adoption of whole slide imaging, which would eventually drive the market during the forecast period. The whole slide imaging technology is capable of providing long-term tissue study, 3D image reconstruction, detailed cell counting and analysis, and stereological analysis. For instance, in October 2020, OptraSCAN launched OS-Ultra, a high-speed whole slide scanner for digital pathology. The device is capable of high-speed and high-quality image scanning in order to streamline the workflow and reduce errors. Such benefits of whole slide imaging for digital pathology are estimated to have positive impact on the market growth. Significant number of market players are focusing on raising investments for digital pathology. As the technology provides an efficient way for superior diagnostics, digital pathology is expected to witness extensive surge in adoption in years to come. For instance, in December 2020, Proscia raised around US$ 23 million through rounds of series funding to accelerate the adoption of digital pathology. Moreover, in April 2019, Deep Lens, a digital pathology start-up raised US$ 13.65 million with the help of series funding. The company operates in cancer clinical trials and raised this amount for consolidation of its digital pathology platform. Such investments are likely to drive the adoption of digital pathology, thereby boosting the market growth by 2028.  

On the contrary, expensive cost associated with installation and maintenance of whole slide imaging. 

• Based on type, the Asia Pacific whole slide imaging market is segmented into hardware, software, and services. The hardware segment held 44.5% market share in 2022, amassing US$ 48.88 million. It is projected to garner US$ 141.08 million by 2028 to expand at 19.3% CAGR during 2022–2028.
• Based on application, the Asia Pacific whole slide imaging market is categorized into telepathology, cytopathology, immunohistochemistry, and hematopathology. The telepathology segment held 42.5% market share in 2022, amassing US$ 46.82 million. It is projected to garner US$ 133.03 million by 2028 to expand at 19.0% CAGR during 2022–2028.
• Based on end user, the Asia Pacific whole slide imaging market is segmented into academic research institutes, hospitals, pharmaceutical and biopharmaceutical companies, and laboratories. The academic research institutes segment held 37.3% market share in 2022, amassing US$ 41.17 million. It is projected to garner US$ 116.82 million by 2028 to expand at 19.0% CAGR during 2022–2028
• Based on country, the Asia Pacific whole slide imaging market has been segmented into Japan, China, India, South Korea, Australia, and Rest of Asia Pacific.  Our regional analysis states that Japan captured 27.1% market share in 2022. It was assessed at US$ 29.91 million in 2022 and is likely to hit US$ 85.31 million by 2028, exhibiting a CAGR of 19.1% during the forecast period.  

Key players dominating the Asia Pacific whole slide imaging market are 3DHISTECH Ltd.; Hamamatsu Photonics K.K.; Indica Labs; Inspirata Inc.; Leica Biosystems Nussloch GmbH (Danaher); Nikon Corporation; Olympus Corporation; Visiopharm A/S; Akoya Biosciences, Inc.; and Koninklijke Philips N.V. among others.

• In March 2020, PANNORAMIC SCAN II digital slide scanner was used to determine the diagnosis of a 66-year-old male patient. This will help the company to improve the presence in China and help Chinese health authorities in their efforts to curb the spreading of the virus.

• In December 2019, Akoya Biosciences, Inc. announced the full commercial release of new products that together form the most complete solution for high-parameter tissue imaging. These include the CODEX® System, and Phenoptics™ 2.0.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com